What an Endometrial Biopsy Can Tell You
An endometrial biopsy provides critical diagnostic information about endometrial tissue, primarily detecting endometrial cancer and hyperplasia with very high sensitivity (99.6% for cancer detection), while also identifying histologic type, tumor grade, hormonal response patterns, infections, and other endometrial pathologies 1, 2.
Primary Diagnostic Capabilities
Cancer Detection and Classification
Endometrial biopsy excels at diagnosing malignancy with exceptional accuracy. The Pipelle and Vabra sampling devices demonstrate sensitivities of 99.6% and 97.1% respectively for detecting endometrial carcinoma 1, 2. When cancer is present, the biopsy reveals:
- Histologic type: Distinguishes between Type 1 (endometrioid adenocarcinomas, representing 80% of cases) and Type 2 (serous, clear cell) carcinomas 1
- Tumor grade: Architectural grading based on solid-to-glandular component ratio (Grade 1: <5% solid; Grade 3: >50% solid) 1
- Molecular features: Can identify microsatellite instability and mutations in PTEN, PIK3CA, K-Ras, β-catenin, and p53 genes 1, 2
- Molecular classification: Modern practice includes immunohistochemistry for p53 and MMR proteins (MLH1, PMS2, MSH2, MSH6) plus POLE hotspot analysis 3
Precancerous Lesions
The biopsy is highly specific (100% in postmenopausal women) for detecting atypical hyperplasia and endometrial hyperplasia, which can precede endometrioid carcinomas 4, 5. This allows risk stratification and early intervention before cancer develops.
Hormonal Assessment
Beyond malignancy, endometrial biopsy evaluates:
- Secretory vs. proliferative endometrium: Assesses ovulatory function and hormonal response
- Luteal phase defects: Identifies inadequate progesterone effect, relevant in infertility evaluation 6
- Endometrial dating: Determines if endometrial development matches menstrual cycle timing
Infectious and Inflammatory Conditions
Biopsy is required for definitive diagnosis of chronic endometritis and can identify specific infections including tuberculosis 7, 6. It also detects non-specific inflammatory changes.
Other Pathologies
The tissue sample can reveal:
- Endometrial atrophy
- Polyps (though blind techniques are unreliable for polyp diagnosis—hysteroscopy is superior) 7
- Rare findings like mesenchymal tumors (though biopsy may miss these wall-based lesions) 8
Critical Limitations to Understand
False-Negative Rate
Office endometrial biopsies have a 10% false-negative rate 1, 9, 8. This is crucial: a negative biopsy in a symptomatic patient must be followed by fractional dilation and curettage under anesthesia 9, 8. The blind sampling nature means focal lesions can be missed 10.
Sampling Adequacy
In 1.79% of cases, the sample may be insufficient for diagnosis 6. Factors affecting sensitivity include:
- Lesion type (focal vs. diffuse)
- Lesion size and quantity
- Presence of intracavitary leiomyoma or polyp
- Uterine malformation
- Surface area of endometrial cavity 10
When Hysteroscopy Is Superior
Hysteroscopy with targeted biopsy should be used when blind biopsy fails, when focal lesions are suspected, or when symptoms persist despite negative biopsy 1. Hysteroscopy has the highest diagnostic accuracy and cost-effectiveness for suspected endometrial malignancy and is essential for diagnosing polyps 7.
Clinical Context for Interpretation
The biopsy information is sufficient for planning definitive treatment in most cases 9, 8. However, it provides only histologic information from the sampled tissue—it does not stage the cancer or assess myometrial invasion depth, cervical involvement, or extrauterine spread. These require surgical staging or advanced imaging (MRI) 3.
For Lynch syndrome screening, universal testing of endometrial tumors for MMR defects is now recommended, with genetic counseling for patients showing deficiencies 8. This has implications for both the patient's cancer management and family screening.
Common pitfall: Assuming a negative biopsy excludes pathology in postmenopausal bleeding. Always correlate with endometrial thickness on ultrasound (≤3-4 mm cutoff) and clinical symptoms 1. Persistent symptoms warrant hysteroscopy regardless of initial biopsy results 4.